Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02389972

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial

Official title:
Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Clinical Trial Summary

The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.

Clinical Trial Description

Breakpoint cluster region (BCR)

Abelson murine leukemia viral oncogene homolog 1 (c-ABL)

Chronic myeloid leukemia (CML) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02389972
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase N/A
Start date April 11, 2013
Completion date July 13, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT01437202 - Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia N/A
Completed NCT02896842 - A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML Phase 2
Withdrawn NCT02421926 - Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
Completed NCT01768689 - Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia N/A
Not yet recruiting NCT02903277 - National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent N/A
Completed NCT03090477 - Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients N/A
Active, not recruiting NCT02885766 - Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene Phase 1/Phase 2
Recruiting NCT01464411 - Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan N/A
Completed NCT01602952 - Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Phase 1/Phase 2
Not yet recruiting NCT02687425 - Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia Phase 2
Completed NCT00171223 - An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha Phase 2
Recruiting NCT04877522 - Asciminib Roll-over Study Phase 4
Completed NCT01511289 - Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Phase 3
Completed NCT02480608 - Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) Phase 1/Phase 2
Completed NCT01774630 - Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) Phase 2